BRTX — Stock Film
STOCK FILMSCENE 1/11BRTX · $0.35
Stock Expert AI presents
BRTX
BioRestorative Therapies, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
BioRestorative Therapies, Inc. A quick introduction.

On the stock market since 2012, it operates in the world of health and science. It has 14 employees. Now — the numbers.

on the stock market since 2012
14 employees
$3.2M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $41.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

WHERE DOES THE MONEY COME FROM?
83%Products
Products 83%Royalty 17%
83% of all revenue comes from a single line: Products.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 67% a year over the last 4 years. Red columns mark years that ended in a loss.

$46K
2021
$120K
2022
$146K
2023
$401K
2024
$360K
2025
In the vault right now:
$0
DEBT: $0
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
10
very weak

Clearly below the class average.

FINANCIAL STRENGTH
28
very weak

Clearly below the class average.

VALUATION
41
weak

Clearly below the class average.

GROWTH
35
weak

Clearly below the class average.

PRICE MOMENTUM
23
very weak

Clearly below the class average.

WORTH WATCHING

Business Quality: Profit power and business quality trail similar companies in the sector.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 44% a year on average.

2
THE BRIGHT SIDE · 2/3
The product is selling

Sales run at $360K a year. A small number, but proof the product has real buyers.

3
THE BRIGHT SIDE · 3/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $14.2M against $360K in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
Trading under $1

The stock sits at $0.35. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, BRTX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: BRTX is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film